<?xml version="1.0"?>
<Articles JournalTitle="Acta Medica Iranica">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>40</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="epublish">
        <Year>2002</Year>
        <Month>06</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">The effects of Methyltestosterone in surgically menopausal women using hormone replacement therapy</title>
    <FirstPage>95</FirstPage>
    <LastPage>99</LastPage>
    <AuthorList>
      <Author>
        <FirstName></FirstName>
        <LastName>Safdarian L</LastName>
        <affiliation locale="en_US"></affiliation>
      </Author>
      <Author>
        <FirstName></FirstName>
        <LastName>Azari S</LastName>
        <affiliation locale="en_US"></affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>09</Month>
        <Day>28</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">In a double blind, parallel-group, clinical trial we compared the effects of conjugated estrogen with estrogen plus methyltestosterone in surgically menopausal women. In this study, 251 women were randomly assigned to one of the two regimens: 1-conjugated estrogen 0.625 mg/day +placebo. 2-conjungated estrogen 0.625 mg/day+methyltestosterone 1.25 mg/day (E+A group). Study parameters were psychologic, urinary and sexual symptoms, lipid profile,liver function test (LFT) and side effects. Significantly greater improvement in psychologic, urinary and sexual symptoms was observed in the E+A group .(P</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/2588</web_url>
    <pdf_url>https://acta.tums.ac.ir/index.php/acta/article/download/2588/2572</pdf_url>
  </Article>
</Articles>
